Evaluation of a Human 3D Airway Tissue Culture Model for the Study of Respiratory Syncytial Virus Infection and the Development of Antiviral Drugs

EDP-938, a Respiratory Syncytial Virus Inhibitor, in a Human Virus Challenge

EDP-938, a Novel Nucleoprotein Inhibitor of Respiratory Syncytial Virus, Demonstrates Potent Antiviral Activities In Vitro and in a Nonhuman Primate Model

EDP-938, a Novel RSV N-inhibitor, Administered Once or Twice Daily was Safe and Demonstrated Robust Antiviral and Clinical Efficacy in a Healthy Volunteer Challenge Study

Preclinical Pharmacokinetic and Pharmacodynamic Characterization of EDP-938, a Novel and Potent Non-Fusion Replication Inhibitor of Respiratory Syncytial Virus (RSV)

EDP 938-101 Phase 2a Study: Human Challenge Study

Discovery and Development of Novel and Potent Non-Fusion Inhibitors of RSV

EDP-938, a Novel, Non-Fusion Replication Inhibitor of Respiratory Syncytial Virus: Preliminary Results of a Phase 1 Study in Healthy Subjects

EDP-938, a Novel Non-Fusion Replication Inhibitor of RSV, Displays a High Barrier to Resistance In Vitro

EDP-938, a Novel Non-Fusion Replication Inhibitor of Respiratory Syncytial Virus, Demonstrates Potent Antiviral Activities both In Vitro and In Vivo